Literature DB >> 14686728

Nanomolar concentrations of epothilone D inhibit the proliferation of glioma cells and severely affect their tubulin cytoskeleton.

A Dietzmann1, D Kanakis, E Kirches, S Kropf, C Mawrin, K Dietzmann.   

Abstract

The purpose of this study was to investigate the potential effects of epothilones (EPOs), a new class of microtubule stabilizing cytotoxic drugs, on glioma cells in vitro. The effects of 1, 10 and 100 nM concentrations of EPO D in four malignant human glioma cell lines were measured using a microtiter-tetrazolium assay. Besides the cell lines U87MG, U138MG and LN405, one cell line was used, which had been derived from a recurrent and therapy-resistant glioblastoma in our laboratory. In addition, changes of the cell morphology were followed by light microscopy and changes in the microtubule and actin cytoskeleton were visualized by a confocal laser microscope. In all four human glioma cell lines, 10 and 100 nM concentrations of the drug, applied for 96 h, lead to a highly significant decrease in the viable cell number (p < 0.001). A mean reduction of the viable cell number between 30% and 40% (60% and 90%) was observed for a drug concentration of 10 nM (100 nM). A round cell morphology occured in most EPO treated cells and the organized network of microtubules was shrunk in these round cells. The tubulin immunostaining now appeared amorphous and was restricted to small perinuclear regions. Large actin filaments also disappeared, but actin staining was present in the whole cytosplasm. These results prove that EPOs have antiproliferative effects in glioma cells and affect their tubulin cytoskeleton, as it was previously observed in several types of carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14686728     DOI: 10.1023/b:neon.0000003679.40609.63

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  13 in total

Review 1.  Epothilones and related structures--a new class of microtubule inhibitors with potent in vivo antitumor activity.

Authors:  K H Altmann; M Wartmann; T O'Reilly
Journal:  Biochim Biophys Acta       Date:  2000-05-17

2.  BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.

Authors:  F Y Lee; R Borzilleri; C R Fairchild; S H Kim; B H Long; C Reventos-Suarez; G D Vite; W C Rose; R A Kramer
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

3.  The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice.

Authors:  T C Chou; O A O'Connor; W P Tong; Y Guan; Z G Zhang; S J Stachel; C Lee; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

4.  Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel.

Authors:  T C Chou; X G Zhang; C R Harris; S D Kuduk; A Balog; K A Savin; J R Bertino; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

5.  Subcellular distribution of epothilones in human tumor cells.

Authors:  R B Lichtner; A Rotgeri; T Bunte; B Buchmann; J Hoffmann; W Schwede; W Skuballa; U Klar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

6.  The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part I: Evaluation of test-specific variables.

Authors:  G Nikkhah; J C Tonn; O Hoffmann; H P Kraemer; J L Darling; R Schönmayr; W Schachenmayr
Journal:  J Neurooncol       Date:  1992-05       Impact factor: 4.130

Review 7.  [New taxanes and epothilone derivatives in clinical trials].

Authors:  François Lavelle
Journal:  Bull Cancer       Date:  2002-04       Impact factor: 1.276

Review 8.  Molecular effects of paclitaxel: myths and reality (a critical review).

Authors:  M V Blagosklonny; T Fojo
Journal:  Int J Cancer       Date:  1999-10-08       Impact factor: 7.396

9.  Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity.

Authors:  P F Muhlradt; F Sasse
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

10.  Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B.

Authors:  T C Chou; X G Zhang; A Balog; D S Su; D Meng; K Savin; J R Bertino; S J Danishefsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-04       Impact factor: 11.205

View more
  4 in total

1.  Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases.

Authors:  Jens Hoffmann; Iduna Fichtner; Margit Lemm; Philip Lienau; Holger Hess-Stumpp; Andrea Rotgeri; Birte Hofmann; Ulrich Klar
Journal:  Neuro Oncol       Date:  2008-09-09       Impact factor: 12.300

2.  Systemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomas.

Authors:  Antonio Silvani; Paola Gaviani; Anna Fiumani; Vidmer Scaioli; Elena Lamperti; Marica Eoli; Andrea Botturi; Andrea Salmaggi
Journal:  J Neurooncol       Date:  2009-04-21       Impact factor: 4.130

Review 3.  Natural Compounds as Modulators of Cell Cycle Arrest: Application for Anticancer Chemotherapies.

Authors:  Natalia Bailon-Moscoso; Gabriela Cevallos-Solorzano; Juan Carlos Romero-Benavides; Maria Isabel Ramirez Orellana
Journal:  Curr Genomics       Date:  2017-04       Impact factor: 2.236

4.  GBM-associated mutations and altered protein expression are more common in young patients.

Authors:  Sherise D Ferguson; Joanne Xiu; Shiao-Pei Weathers; Shouhao Zhou; Santosh Kesari; Stephanie E Weiss; Roeland G Verhaak; Raymond J Hohl; Geoffrey R Barger; Sandeep K Reddy; Amy B Heimberger
Journal:  Oncotarget       Date:  2016-10-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.